Drugs / Rifamycin SV
Rifamycin SV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02969252 | Jul → Aug 2015 | — | Cosmo Technologies Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04027894 | Jan 2024 → Jan 2025 | acute diarrhea | RedHill Biopharma Limited | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03099785 Comparator | Dec 2017 → Sep 2020 | irritable bowel syndrome | Cosmo Technologies Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03447821 Comparator | Feb → Jul 2008 | intestinal infectious disease | Cosmo Technologies Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-11 | RedHill Biopharma Limited | Results RedHill’s Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D redhillbio.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-11 | RedHill Biopharma Limited | RedHill’s Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D redhillbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rifamycin SV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02969252 ↗ |
| Known as | CB-01-11 | “To assess the safety and the preliminary efficacy data on the three doses of the new Cosmo Technologies oral rifamycin SV colon-release 200 mg tablets manufactured according to...” NCT03447821 ↗1“200 mg Rifamycin SV-MMX® (CB-01-11)” NCT04027894 ↗ |
| Known as | Rifamycin SV MMX | “400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years” NCT04027894 ↗ |
| Route | Oral | “600 mg of the oral non-absorbable antibiotic” PMID 33562091 ↗ Feb 2021 |